Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials
I'm LongbridgeAI, I can summarize articles.Alto Neuroscience reported approximately $244.2 million in cash as of June 30, 2026, and announced plans to expand ALTO-207 trials for treatment-resistant depression. While analysts maintain a 'Buy' rating with a $44 target, TipRanks' AI suggests a 'Neutral' stance due to pre-revenue status and cash burn, despite a strong balance sheet and positive technicals.
Alto Neuroscience, Inc. ( (ANRO) ) has provided an announcement.
On July 13, 2026, Alto Neuroscience, Inc. reported preliminary estimates that its cash, cash equivalents and restricted cash totaled approximately $244.2 million as of June 30, 2026, noting that these figures have not yet been audited and could change materially after full accounting procedures. The company also disclosed plans to accelerate and expand clinical development of its lead program ALTO-207, including an additional planned Phase 3 trial of the drug as a monotherapy for treatment-resistant depression, underscoring a commitment to advance its pipeline using its substantial liquidity position.
These developments reflect a combination of financial strength and strategic focus on late-stage clinical trials, which may support Alto Neuroscience’s efforts to enhance its positioning in the competitive depression treatment landscape and could be significant for investors tracking its progress in bringing novel therapies to market.
The most recent analyst rating on (ANRO) stock is a Buy
with a $44.00 price target.
To see the full list of analyst forecasts on Alto Neuroscience, Inc. stock,
see the ANRO Stock Forecast page.
Spark’s Take on ANRO Stock
According to Spark, TipRanks’ AI Analyst, ANRO is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn), partially offset by a strong, low-debt balance sheet. Technicals are a notable positive with the stock trading above key moving averages and positive momentum indicators. Valuation is unattractive/less meaningful due to negative earnings, while corporate events are mixed following a clinical miss and strategic reprioritization.
To see Spark’s full report on ANRO stock,
click here.
More about Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates in the biopharmaceutical sector, focusing on the clinical development of neuroscience-based therapeutics. Its pipeline includes advanced drug candidates such as ALTO-207, which targets treatment-resistant depression, positioning the company within the mental health and central nervous system disorders market.
Average Trading Volume: 434,743
Technical Sentiment Signal: Buy
Current Market Cap: $929.3M